CSL Limited
https://www.csl.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CSL Limited
Seven Potential Blockbuster Approvals To Look Out For In 2023
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
ESMO: Positive Results Buoy Chinese Oncology Developers' Global Hopes
Promising new clinical results presented at ESMO are likely to help several Chinese firms gain traction to take their new drug candidates into global markets, including the US.
Can Moderna Pull Off More Disruptive Innovation? Flu And RSV Shots Are Next Test
Moderna needs to develop new mRNA-based therapies beyond COVID-19, and flu and RSV will be the big readouts in 2023.
Future For Spexis Looks Far From Secure
Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Medical Devices
- Diagnostic Equipment & Supplies
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Other Names / Subsidiaries
-
- bioCSL
- CSL Behring
- CSL Behring Mexico
- CSL Biotherapies
- CSL Bioplasma
- Seqirus
- Wuhan Zhong Yuan Rui De Biological Products
- Ruide
- Calimmune, Inc.
- Vitaeris Inc.
- Zenyth Therapeutics Ltd.
- CSL, Ltd.